- Asthma and lung cancer risk: a systematic investigation by the International Lung Cancer Consortium2012 | First Faculty of Medicine
- BIBF 1120 for the therapy of non-small cell lung cancer2011 | Third Faculty of Medicine
- Previous Lung Diseases and Lung Cancer Risk: A Pooled Analysis From the International Lung Cancer Consortium2012 | First Faculty of Medicine
- 15th CELCC - Central European Lung Cancer Conference. Praha 28. - 30. 11. 20152016 | First Faculty of Medicine
- Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium2012 | First Faculty of Medicine
- Detection of morphological and genetic changes of the bronchial mucosa by autofluorescence bronchoscopy in heavy smokers2007 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Screening karcinomu plic a jeho implementace v podmínkách univerzitního centra2022 | First Faculty of Medicine
- Anaemia during chemoradiotherapy for advanced non-small cell lung cancer - correlation of incidence and clinical importance2002 | First Faculty of Medicine
- Silicosis and carcinogenic risk in workers in the Czech Republic2009 | First Faculty of Medicine
- Co nového v imunoterapii na WCLC 20192019 | Second Faculty of Medicine
- Role of histology in the choice of treatment for advanced non-small-cell lung cancer2010 | Publication without faculty affiliation
- Pacient s generalizovaným nemalobuněčným karcinomem plic s fúzí ROS1 s výbornou klinickou i zobrazovací odpovědí na léčbě entrektinibem2021 | Publication without faculty affiliation
- Targeted treatment and immunotherapy of advanced non-small cell lung cancer2022 | First Faculty of Medicine
- Virtual WCLC 2020 and Immunotherapy - Conference Report2021 | Publication without faculty affiliation
- Editorial2021 | First Faculty of Medicine
- Atezolizumab in the treatment of lung cancer +12020 | Publication without faculty affiliation
- Pulmonary function tests before lung resection - case report2019 | First Faculty of Medicine
- Ground-breaking ADAURA trial - osimertinib as adjuvant therapy of EGFR-mutated NSCLC2022 | First Faculty of Medicine
- Treatment of lung cancer with targetable mutations - new drugs and indications2023 | First Faculty of Medicine
- KRAS mutations in non-small cell lung cancer and options of treatment2020 | First Faculty of Medicine
- Amivantamab in non‐small cell lung cancer treatment2023 | Third Faculty of Medicine
- International Lung Cancer Consortium: Coordinated association study of 10 potential lung cancer susceptibility variants2010 | First Faculty of Medicine
- Patient with NSCLC and brain metastases and positive reassortment ALK treated with alectinib - case report2020 | Publication without faculty affiliation
- Lorlatinib in the treatment of non‑small cell lung cancer2020 | Publication without faculty affiliation
- Treatment of ALK positive non-small cell lung cancer2021 | First Faculty of Medicine
- The current standard of NSCLC pathological examination in the Czech Republic2022 | Faculty of Medicine in Hradec Králové
- Afatinib - drug profile2017 | Publication without faculty affiliation
- Rare case of choroidal metastasis in ALK-positive NSCLC that responds to crizotinib2019 | First Faculty of Medicine
- Future of lung cancer treatment2021 | First Faculty of Medicine